Literature DB >> 1334967

Effects of cyclosporine A on the hypothalamic-pituitary-adrenal axis and anterior pituitary interleukin-6 mRNA expression during chronic inflammatory stress in the rat.

A Stephanou1, N J Sarlis, R A Knight, S L Lightman, H S Chowdrey.   

Abstract

In the rat, adjuvant arthritis (AA) is an inflammatory joint disease associated with chronic stimulation of the hypothalamic-pituitary-adrenal (HPA) axis. We have investigated the effects of the immunosuppressive agent cyclosporine A (CsA) on plasma levels of adrenocorticotropin (ACTH) and corticosterone (B), as well as on anterior pituitary proopiomelanocortin (POMC) and interleukin (IL)-6 mRNA accumulation in control and adjuvant-injected animals. In control animals, CsA reduced basal anterior pituitary POMC and IL-6 mRNA and decreased plasma levels of ACTH and B. Adjuvant-injected animals that were treated with CsA showed no clinical signs of AA. Moreover, CsA inhibited the arthritis-induced increases in pituitary POMC and IL-6 mRNA levels and in circulating ACTH and B. In vitro, CsA reduced the POMC mRNA content of cultured anterior pituitary cells and diminished the stimulatory effects of corticotropin-releasing hormone (CRH) on POMC mRNA expression and ACTH secretion from these cells. These data indicate that CsA has a direct action on the HPA axis and also reduces the activation of the HPA axis seen in chronic inflammatory arthritis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334967     DOI: 10.1016/0165-5728(92)90072-s

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice.

Authors:  J Raber; R D O'Shea; F E Bloom; I L Campbell
Journal:  J Neurosci       Date:  1997-12-15       Impact factor: 6.167

2.  Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis.

Authors:  H S Chowdrey; P J Larsen; M S Harbuz; D S Jessop; G Aguilera; D J Eckland; S L Lightman
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.